LUMAKRAS® COMBINED WITH VECTIBIX® SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER Market News
LUMAKRAS®/LUMYKRAS® DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER Market News
Five-Year Data for Merck's KEYTRUDA® Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer Life Science Investing
New Late-Breaking Results from Phase 3 Trials of SKYRIZI® Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 Pharmaceutical Investing
Bristol Myers Squibb Announces New Sotyktu Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis Pharmaceutical Investing
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® Plus LENVIMA® Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Life Science Investing
U.S. Food and Drug Administration Approves Sotyktu , Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis Pharmaceutical Investing
The Gummy Project to Be Featured on "This Is BC" with Jay Durant on Global News Hour's Flagship Broadcast Life Science Investing
Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference Psychedelics Investing
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
